Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00783224 | A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512) | PHASE3 | COMPLETED | 351 | — | — | Sep 1, 2005 | Dec 1, 2005 | Feb 9, 2022 | - | — |
The nasal symptoms (sneezing attacks, rhinorrhea, nasal congestion and itching) were rated in 4 grades (+++: 3 points, ++: 2 points, +: 1 point, -: 0 point) based on the evaluation criteria for nasal symptoms. Total possible best score is 0 points, total possible worst score is 12 points.
| Arm | Type | Description |
|---|---|---|
| Mometasone Furoate Placebo (PLAMF) | PLACEBO_COMPARATOR | Placebo to mometasone furoate nasal spray, made to be indistinguishable from mometasone furoate nasal spray |
| Fluticasone Propionate Placebo (PLAFP) | PLACEBO_COMPARATOR | Placebo to fluticasone propionate nasal spray, made to be indistinguishable from fluticasone propionate nasal spray |
| Mometasone Furoate (MF) | EXPERIMENTAL | Mometasone furoate nasal spray 200 μg/day(QD) |
| Fluticasone Propionate (FP) | ACTIVE_COMPARATOR | Fluticasone Propionate nasal spray 200 μg/day, twice per day (BID) |
| Name | Type | Description |
|---|---|---|
| Placebo for MF | DRUG | Placebo to mometasone furoate nasal spray, indistinguishable from mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks |
| Placebo for FP | DRUG | Placebo to fluticasone nasal spray, indistinguishable from fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks |
| Mometasone | DRUG | Mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks |
| Fluticasone | DRUG | Fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks |
Inclusion Criteria: Patients with perennial allergic rhinitis meeting all of the followings. * Patients with symptoms of perennial allergic rhinitis, the severity of which is moderate or severer according to the severity grading provided in the "Guidelines for the Management of Allergic Rhinitis i...